Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HEPATITIS C (HCV) Clear all
Completed Phase 2 Interventional

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

NCT00097435
View directory record Official record
Conditions
Hepatitis C
Interventions
Albuferon, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jun 10, 2026, 8:06 AM EDT
Completed No phase listed Observational

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850
View directory record Official record
Conditions
Hepatitis C, Hepatitis B
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 8:06 AM EDT
Not listed Phase 4 Interventional

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

NCT03364725
View directory record Official record
Conditions
Hepatitis C, Addict Heroin
Interventions
Glecaprevir-pibrentasvir
Drug
Lead sponsor
Id Care
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

NCT01924949
View directory record Official record
Conditions
Hepatitis C
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

NCT04198584
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VC-CBCS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

GS-7977 With Ribavirin for Hepatitis C (SPARE)

NCT01441180
View directory record Official record
Conditions
Hepatitis C
Interventions
GS7977, RBV
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Jun 10, 2026, 8:06 AM EDT
Terminated Not applicable Interventional

Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital

NCT03441542
View directory record Official record
Conditions
Hepatitis C
Interventions
Data-assisted Case Navigation, Standard of Care
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

NCT01830205
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

NCT01994486
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir and Sofosbuvir
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

Effective Treatment of Hepatitis C in Substance Users

NCT00633243
View directory record Official record
Conditions
Hepatitis C, Opiate Dependence
Interventions
Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

NCT00393276
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Twinrix, Decavac
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

NCT01329978
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Science Aspects of Rapid Test Acceptance

NCT01317784
View directory record Official record
Conditions
HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions
Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only
Device
Lead sponsor
California State University, Long Beach
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Jun 10, 2026, 8:06 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jun 10, 2026, 8:06 AM EDT
Completed No phase listed Observational

Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

NCT01429155
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 28B genotype
Genetic
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Jun 10, 2026, 8:06 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Jun 10, 2026, 8:06 AM EDT
Not listed Phase 2 Interventional

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

NCT00225537
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
4-Methylumbelliferone (Heparvit®)
Drug
Lead sponsor
MTmedical Institute of Health
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Jun 10, 2026, 8:06 AM EDT
Withdrawn Phase 2 Interventional

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

NCT01142700
View directory record Official record
Conditions
Chronic Hepatitis C Virus Genotype 1
Interventions
BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening

NCT02833298
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC, Hepatitis C, HCV
Interventions
Automated reminders, Patient navigation
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

NCT01330316
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335, PegIFN/RBV
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

NCT00110799
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions
SB497115, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jun 10, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

NCT00971308
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-824393
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Anaheim, California • Cypress, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jun 10, 2026, 8:06 AM EDT